AMULET IDE: New Research Compares WatchMan and Amulet Devices Providing New Evidence

Recently, at the TCT Congress results from the SWISS-APERO study comparing Watchman and Amulet devices were presented. Now, a new study, Amulet IDE—published in Circulation—, compared both devices on a large number of patients.

AMULET Die: Un nuevo estudio compara los dispositivos Watchman y Amulet y arroja nueva evidencia

Amulet IDE was designed to evaluate the safety and efficacy of dual-seal mechanism device Amulet compared with the Watchman (a widely used tool in clinical practice).

In this sense, the Amulet device was non-inferior in terms of safety and efficacy to prevent stroke in patients with nonvalvular atrial fibrillation compared with the Watchman device. Atrial appendage occlusion was superior with Amulet—a result also observed in SWISS-APERO.

In this study, 1878 patients with nonvalvular atrial fibrillation and at high risk of stroke were randomized to receive either device. The primary safety endpoint was a composite of procedure-related complications, all-cause mortality, or major bleeding.

The efficacy endpoint was a composite of ischemic stroke or systemic embolism at 18 months. Atrial appendage seal at 45 days was also considered.

In terms of safety, Amulet proved to be non-inferior to Watchman (14.5% vs. 14.7%; p < 0.001).


Read also: TCT 2021 | SWISS-APERO: Difference in Leaks between the Amulet and the Watchman.


However, results were similar for major bleeding and death (10.6% vs. 10.0%, and 3.9% vs. 5.1%, respectively).

Procedure-related complications (pericardial effusion and device embolization) were higher with Amulet (4.5% vs. 2.5%).

Conclusion

The Amulet atrial appendage occluder device was non-inferior in terms of safety and efficacy for stroke prevention in patients with nonvalvular atrial fibrillation. Peri-procedural complications were higher with Amulet, but decreased with increased operator experience.

amulet-die

Original Title: Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE).

Reference: Dhanunjaya Lakkireddy et al. Circulation. 2021 Nov 9;144(19):1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...